In a positive development, Ahmedabad based pharmaceutical major Zydus Cadila has reached out to the Drugs Controller General of India (DCGI), seeking the nod to begin Phase-III clinical trials of its COVID-19 vaccine candidate called 'ZyCoV-D', reports Times of India.
The plasmid DNA vaccine candidate has been found to be safe, well-tolerated and immunogenic in the Phase-I and Phase-II clinical trials. Now, the company is looking to conduct a massive Phase-III clinical trial of the vaccine with around 30,000 volunteers.
In the Phase-II clinical trial, the company tested the vaccine on over 1,000 healthy adult volunteers as a part of the adaptive Phase-I and Phase-II dose-escalation, multi-centric, randomised and double-blind placebo-controlled study.
"We are optimistic of Phase-III clinical trial outcomes as well and that we would be able to start the production of the Novel Vaccine on its successful completion," Zydus' chairman Pankaj R Patel said.
It should be noted that the company has also claimed that the DNA vaccine platform established by it can also be used to modify the vaccine in a couple of weeks in case the virus mutates.
As you are no doubt aware, Swarajya is a media product that is directly dependent on support from its readers in the form of subscriptions. We do not have the muscle and backing of a large media conglomerate nor are we playing for the large advertisement sweep-stake.
Our business model is you and your subscription. And in challenging times like these, we need your support now more than ever.
We deliver over 10 - 15 high quality articles with expert insights and views. From 7AM in the morning to 10PM late night we operate to ensure you, the reader, get to see what is just right.
Becoming a Patron or a subscriber for as little as Rs 1200/year is the best way you can support our efforts.